311 related articles for article (PubMed ID: 37641627)
1. Roles of Gut Microbiota in Alcoholic Liver Disease.
Zhang D; Liu Z; Bai F
Int J Gen Med; 2023; 16():3735-3746. PubMed ID: 37641627
[TBL] [Abstract][Full Text] [Related]
2. Gut microbiota-modulating agents in alcoholic liver disease: Links between host metabolism and gut microbiota.
Jung JH; Kim SE; Suk KT; Kim DJ
Front Med (Lausanne); 2022; 9():913842. PubMed ID: 35935787
[TBL] [Abstract][Full Text] [Related]
3. Intestinal HIF-1α deletion exacerbates alcoholic liver disease by inducing intestinal dysbiosis and barrier dysfunction.
Shao T; Zhao C; Li F; Gu Z; Liu L; Zhang L; Wang Y; He L; Liu Y; Liu Q; Chen Y; Donde H; Wang R; Jala VR; Barve S; Chen SY; Zhang X; Chen Y; McClain CJ; Feng W
J Hepatol; 2018 Oct; 69(4):886-895. PubMed ID: 29803899
[TBL] [Abstract][Full Text] [Related]
4. Are Probiotics Effective in Targeting Alcoholic Liver Diseases?
Hong M; Han DH; Hong J; Kim DJ; Suk KT
Probiotics Antimicrob Proteins; 2019 Jun; 11(2):335-347. PubMed ID: 29687200
[TBL] [Abstract][Full Text] [Related]
5. The Role of Gut Bacteria and Fungi in Alcohol-Associated Liver Disease.
Chen L; Zhu Y; Hou X; Yang L; Chu H
Front Med (Lausanne); 2022; 9():840752. PubMed ID: 35308525
[TBL] [Abstract][Full Text] [Related]
6. Probiotics-Based Treatment as an Integral Approach for Alcohol Use Disorder in Alcoholic Liver Disease.
Fuenzalida C; Dufeu MS; Poniachik J; Roblero JP; Valenzuela-Pérez L; Beltrán CJ
Front Pharmacol; 2021; 12():729950. PubMed ID: 34630107
[TBL] [Abstract][Full Text] [Related]
7. The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases.
An L; Wirth U; Koch D; Schirren M; Drefs M; Koliogiannis D; Nieß H; Andrassy J; Guba M; Bazhin AV; Werner J; Kühn F
J Gastrointest Surg; 2022 Mar; 26(3):671-683. PubMed ID: 34734369
[TBL] [Abstract][Full Text] [Related]
8. Alcohol or Gut Microbiota: Who Is the Guilty?
Meroni M; Longo M; Dongiovanni P
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540133
[TBL] [Abstract][Full Text] [Related]
9. Bisphenol A exposure induces gut microbiota dysbiosis and consequent activation of gut-liver axis leading to hepatic steatosis in CD-1 mice.
Feng D; Zhang H; Jiang X; Zou J; Li Q; Mai H; Su D; Ling W; Feng X
Environ Pollut; 2020 Oct; 265(Pt A):114880. PubMed ID: 32540565
[TBL] [Abstract][Full Text] [Related]
10. Microbiome-Based Metabolic Therapeutic Approaches in Alcoholic Liver Disease.
Hyun JY; Kim SK; Yoon SJ; Lee SB; Jeong JJ; Gupta H; Sharma SP; Oh KK; Won SM; Kwon GH; Cha MG; Kim DJ; Ganesan R; Suk KT
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955885
[TBL] [Abstract][Full Text] [Related]
11. The gut-liver axis in liver disease: Pathophysiological basis for therapy.
Albillos A; de Gottardi A; Rescigno M
J Hepatol; 2020 Mar; 72(3):558-577. PubMed ID: 31622696
[TBL] [Abstract][Full Text] [Related]
12. Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice.
Ferrere G; Wrzosek L; Cailleux F; Turpin W; Puchois V; Spatz M; Ciocan D; Rainteau D; Humbert L; Hugot C; Gaudin F; Noordine ML; Robert V; Berrebi D; Thomas M; Naveau S; Perlemuter G; Cassard AM
J Hepatol; 2017 Apr; 66(4):806-815. PubMed ID: 27890791
[TBL] [Abstract][Full Text] [Related]
13. Gut microbiota in alcoholic liver disease: pathogenetic role and therapeutic perspectives.
Malaguarnera G; Giordano M; Nunnari G; Bertino G; Malaguarnera M
World J Gastroenterol; 2014 Nov; 20(44):16639-48. PubMed ID: 25469033
[TBL] [Abstract][Full Text] [Related]
14. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
[TBL] [Abstract][Full Text] [Related]
15. Targeting the gut microbiota to treat alcoholic liver diseases: evidence and promises.
Leclercq S; de Timary P; Stärkel P
Acta Gastroenterol Belg; 2020; 83(4):616-621. PubMed ID: 33321019
[TBL] [Abstract][Full Text] [Related]
16. Microbiota-based treatments in alcoholic liver disease.
Sung H; Kim SW; Hong M; Suk KT
World J Gastroenterol; 2016 Aug; 22(29):6673-82. PubMed ID: 27547010
[TBL] [Abstract][Full Text] [Related]
17. Alcohol, microbiome, life style influence alcohol and non-alcoholic organ damage.
Neuman MG; French SW; Zakhari S; Malnick S; Seitz HK; Cohen LB; Salaspuro M; Voinea-Griffin A; Barasch A; Kirpich IA; Thomes PG; Schrum LW; Donohue TM; Kharbanda KK; Cruz M; Opris M
Exp Mol Pathol; 2017 Feb; 102(1):162-180. PubMed ID: 28077318
[TBL] [Abstract][Full Text] [Related]
18. Alcohol, Inflammation, and Microbiota in Alcoholic Liver Disease.
Dukić M; Radonjić T; Jovanović I; Zdravković M; Todorović Z; Kraišnik N; Aranđelović B; Mandić O; Popadić V; Nikolić N; Klašnja S; Manojlović A; Divac A; Gačić J; Brajković M; Oprić S; Popović M; Branković M
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835145
[TBL] [Abstract][Full Text] [Related]
19. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease.
Woodhouse CA; Patel VC; Singanayagam A; Shawcross DL
Aliment Pharmacol Ther; 2018 Jan; 47(2):192-202. PubMed ID: 29083037
[TBL] [Abstract][Full Text] [Related]
20. Compound Probiotic Ameliorates Acute Alcoholic Liver Disease in Mice by Modulating Gut Microbiota and Maintaining Intestinal Barrier.
Liu H; Kang X; Yang X; Yang H; Kuang X; Ren P; Yan H; Shen X; Kang Y; Li L; Wang X; Guo L; Tong M; Fan W
Probiotics Antimicrob Proteins; 2023 Feb; 15(1):185-201. PubMed ID: 36456838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
